The results of a Phase I clinical trial using a first-in-class HIF-2alpha inhibitor called PT2385 are reported in the Journal of Clinical Oncology. The drug, developed by Peloton Therapeutics, showed activity in highly pretreated patients and minimal side-effects. KCP researcher, Dr. Kevin Courtney, was the UTSW site PI and corresponding author of the report. Press Release
